Karyopharm announces dosing of first patient in a new phase 2 study evaluating single-agent selinexor versus physician's choice in previously treated myelofibrosis

Newton, mass., dec. 6, 2021 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq:kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patient in a new phase 2 study evaluating oral selinexor, the company's first-in-class, oral selective inhibitor of nuclear export (sine) compound, as a monotherapy versus physician's choice in patients with myelofibrosis (mf) previously treated with a jak 1/2 inhibitor (xport-mf-035; nct04562870).
KPTI Ratings Summary
KPTI Quant Ranking